Amalgamated Financial’s Anavex Life Sciences AVXL Stock Holding History

Amalgamated Financial’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$134K	Buy	+10,923	New	+$134K	﹤0.01%	2046

Other funds holding AVXL

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Amalgamated Financial's AVXL Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Anavex Life Sciences (AVXL) in Q1 2022: 10,923 shares worth $134K. The stake represents ﹤0.01% of the portfolio and ranks #2046 among its holdings.

139 funds tracked by Wall St. Rank hold AVXL as of Q1 2022.

Amalgamated Financial held 10,923 shares of Anavex Life Sciences worth $134K as of Q1 2022.
Anavex Life Sciences was a new Amalgamated Financial position in Q1 2022.
Anavex Life Sciences made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2046 holding.
139 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.